Erin Taylor is a senior economist at RAND. Her research addresses a broad range of health care insurance, prescription drug, and care quality issues, including the impact of insurance benefit design on the use of insulin, opioids, and specialty drugs. Taylor is currently co-principal investigator of a National Institute on Aging (NIA) R01 examining access to medications to treat opioid use disorder in Medicare beneficiaries. She also co-leads a project for the state of California to conduct analyses using the new all-payer claims database and is the principal investigator of a foundation-funded project to assess the impact of the recent Medicare Part D benefit redesign on beneficiaries with chronic conditions. Other current project work includes the multi-year evaluation of the Medicare Advantage Value-Based Insurance Design model test, for which she serves as the quantitative task lead. Previously, she was co-project lead of the Part D Senior Savings (PDSS) Model evaluation, which found that reducing copays for insulins increased utilization and adherence and lowered costs to the government, and was co-project lead for the CAHPS for ACOs and MIPS survey project.
Taylor received her Ph.D. in health economics from the University of Pennsylvania and her M.S.P.H. from the University of North Carolina. Prior to pursuing her Ph.D., she worked in the Office of Legislation within the Centers for Medicare & Medicaid Services.
Ph.D. in health economics, University of Pennsylvania; M.S.P.H., University of North Carolina at Chapel Hill; B.A. in economics, St. Mary's College of Maryland
Spanish
